Sec Form 13G Filing - BRADBURY DANIEL filing for CASTLE BIOSCIENCES INC (CSTL) - 2021-02-16

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

CASTLE BIOSCIENCES, INC.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

14843C 105

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

1	NAMES OF REPORTING PERSONS
	Daniel Bradbury
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)☐
	(b)☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0 Shares
		6	SHARED VOTING POWER
			743,420 Shares (1)
		7	SOLE DISPOSITIVE POWER
			0 Shares
		8	SHARED DISPOSITIVE POWER
			743,420 Shares (1)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	743,420 Shares (1)
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.00% (2)
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

(1)          Includes (a) 12,229 shares of common stock issuable within 60 days of December 31, 2020 upon the exercise of stock options held by the Reporting Person, (b) 415,606 shares of common stock beneficially owned by BioBrit LLC, of which Mr. Bradbury is a managing member, (c) 157,804 shares held in the name of the Annette Bradbury Irrevocable Descendant's Trust, of which the Reporting Person is a Trustee, and (d) 157,781 shares held in the name of the Daniel Bradbury Irrevocable Descendant's Trust, of which the Reporting Person is a Trustee.

 

(2)          This percentage is calculated based on 24,755,765 shares of common stock outstanding as of December 18, 2020, based on 20,155,765 shares of common stock outstanding on December 11, 2020 as reported in the Issuer’s Prospectus dated December 14, 2020 included in the Registration Statement on Form S-3 filed on December 14, 2020 after giving effect to the completion of the Issuer’s public offering of 4,600,000 shares of common stock, including the full exercise of the underwriters’ over-allotment option, as reported in the Issuer’s press release published on December 18, 2020.

 

1	NAMES OF REPORTING PERSONS
	BioBrit, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)☐
	(b)☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	California
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0 Shares
		6	SHARED VOTING POWER
			743,420 Shares
		7	SOLE DISPOSITIVE POWER
			0 Shares
		8	SHARED DISPOSITIVE POWER
			743,420 Shares
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	743,420 Shares
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				< div style="text-align: left">
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.00% (1)
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	OO

(1)          This percentage is calculated based on 24,755,765 shares of common stock outstanding as of December 18, 2020, based on 20,155,765 shares of common stock outstanding on December 11, 2020 as reported in the Issuer’s Prospectus dated December 14, 2020 included in the Registration Statement on Form S-3 filed on December 14, 2020 after giving effect to the completion of the Issuer’s public offering of 4,600,000 shares of common stock, including the full exercise of the underwriters’ over-allotment option, as reported in the Issuer’s press release published on December 18, 2020.

 

Item 1(a).		Name of Issuer: Castle Biosciences, Inc.
Item 1(b).		Address of Issuer’s Principal Executive Offices: 820 S. Friendswood Drive, Suite 201 Friendswood, TX  77546
Item 2(a).		Names of Persons Filing: Daniel Bradbury BioBrit, LLC
Item 2(b).		Address of Principal Business Office, or, if none, Residence: The address of Daniel Bradbury and BioBrit LLC is: 2314 Rue Adriane, La Jolla, CA 92037
Item 2(c).		Citizenship: Daniel Bradbury: United States of America BioBrit LLC: California

Item 2(d).		Title of Class of Securities: Common Stock
Item 2(e).		CUSIP No.: 14843C 105
Item 3.		Not Applicable.
Item 4.	Ownership

The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G.  Ownership is stated as of December 31, 2020.  The ownership percentage is calculated based on 24,755,765 shares of common stock outstanding as of December 18, 2020, based on 20,155,765 shares of common stock outstanding on December 11, 2020  as reported in the Issuer’s Prospectus dated December 14, 2020 included in the Registration Statement on Form S-3 filed on December 14, 2020 after giving effect to the completion of the Issuer’s public offering of 4,600,000 shares of common stock, including the full exercise of the underwriters’ over-allotment option, as reported in the Issuer’s press release published on December 18, 2020.

(1) This percentage is calculated based on 24,755,765 shares of common stock outstanding as of December 18, 2020, based on 20,155,765 shares of common stock outstanding on December 11, 2020  as reported in the Issuer’s Prospectus dated December 14, 2020 included in the Registration Statement on Form S-3 filed on December 14, 2020 after giving effect to the completion of the Issuer’s public offering of 4,600,000 shares of common stock, including the full exercise of the underwriters’ over-allotment option, as reported in the Issuer’s press release published on December 18, 2020.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☐

Not applicable

Not applicable

Not applicable

Not applicable

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

Exhibit:

99.1:

Joint Filing Agreement